Your session is about to expire
← Back to Search
Pembrolizumab for Breast Cancer
Study Summary
This trial looks at how well pembrolizumab works for treating patients with hormone receptor positive inflammatory breast cancer who are receiving hormone therapy and didn't achieve a pathological complete response to chemotherapy.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have an immune system disorder or am on drugs that weaken my immune system.I am 18 years old or older.I have an autoimmune disease that needed treatment in the last 3 months.I have had pneumonitis treated with steroids or have it now.I have been treated with specific antibodies before.I have been diagnosed with HIV.I have an active Hepatitis B or C infection.I have not received a live vaccine in the last 30 days.I have had issues with my digestive system or a history of colitis.I need daily corticosteroids through pills or infusion.My cancer did not fully respond to chemotherapy before surgery.My cancer is not HER2 positive.I am fully active or can carry out light work.I will start or have finished radiation and will begin hormone therapy within 4 weeks.I started hormone therapy within 6 months after radiation and can begin the study drug within 4 weeks after screening.I am currently being treated for an infection.My breast cancer has been confirmed through tissue examination.My breast cancer is confirmed as inflammatory by international standards.My organ functions are within normal ranges according to recent tests.My cancer is positive for estrogen or progesterone receptors.I have had cancer before, but it's one of the exceptions.I am still experiencing side effects from previous treatments.My breast cancer has spread beyond the breast and nearby lymph nodes.I haven't had a heart attack or severe heart issues in the last 6 months.
- Group 1: Treatment (pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any similar Pembrolizumab trials that have taken place in the past?
"Pembrolizumab is being trialed in 1000 different studies at the moment, 122 of which are Phase 3 clinical trials. Most of the trials for Pembrolizumab are based in Houston, Texas, but there are 35906 locations running trials for this treatment."
Has the FDA acknowledged Pembrolizumab as an official treatment?
"Pembrolizumab has not yet been proven effective, however, there is some data indicating that it is safe. Our team has given it a score of 2."
Are new participants being welcomed into the experiment as we speak?
"Unfortunately, this trial is not looking for new participants at the moment. However, it is still active, with the most recent update being on September 30th, 2022. There are 2366 trials actively recruiting breast cancer patients and 1000 trials using Pembrolizumab seeking participants."
Share this study with friends
Copy Link
Messenger